16807-21-9Relevant articles and documents
CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF
-
Paragraph 0354; 0357, (2019/04/05)
Disclosed are a class of compounds as a caspase inhibitor, and in particular the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound in treating caspase-related diseases.
DIHYDROIMIDAZOTHIAZOLE DERIVATIVES
-
Page/Page column 31, (2008/06/13)
Compounds of formula (I): or pharmaceutically acceptable salts thereof, exhibit 5-HT1A agonism in addition to noradrenaline reuptake inhibition and optionally also 5-HT reuptake inhibition are useful for the treatment of obesity.
Processes and intermediate compounds for the preparation of 2-(N,N-disubstituted) amino-4-(perfluoroalkyl)-1, 3- oxazin-6-one and 6-(perfluoroalkyl) uracil compounds
-
, (2008/06/13)
An improved process and intermediate compounds for the preparation of 2-(N,N-disubstituted)amino-4-(perfluoroalkyl)-1,3-oxazin-6-one compounds having the structural formula I and an improved process for the preparation of 6-(perfluoroalkyl)uracil compound